Immunome
IMNM
19.10
-0.22
-1.11%
Immunome
US · IMNM
#2671 by market cap
Listed 2020
19.10
-0.22
-1.11%
Live - 5344 symbols - heartbeat 545s ago
· 2026-10-08 08:07
Pre-market
18.98
-0.60%
After-hours
19.10
0.00%
- Market cap
- 2.25B
- P/E (TTM)i
- -7.55
- P/Bi
- 4.29
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on IMNM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 26.20, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -23.23% YoY
Margins
- Operating margin
- -3,228.83%
- Net margin
- -3,059.99%
Key ratios & quality
- Altman Z-Scorei
- 26.20
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0 | 14.02M | 9.04M | 6.94M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 866.00K | 1.53M | 4.78M | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Research & development | 6.88M | 8.82M | 7.49M | 14.11M | 23.27M | 103.89M | 281.89M | 187.29M |
| Operating profit | -7.74M | -10.35M | -12.26M | -25.20M | -36.90M | -109.53M | -305.80M | -224.11M |
| Pretax profit | -7.85M | -10.44M | -17.84M | -24.71M | -36.90M | -106.81M | -292.96M | -212.39M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -7.85M | -10.44M | -17.84M | -24.71M | -36.90M | -106.81M | -292.96M | -212.39M |
| Basic EPS | -2 | -2 | -5 | -2 | -3 | -5 | -5 | -2 |
| Diluted EPS | -1.79 | -1.82 | -5.26 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.93M | 4.02M | 0 | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.69M | 10.04M | 10.95M | 12.09M | 12.95M | 18.25M |
| Research & development | 36.87M | 40.45M | 49.19M | 60.77M | 46.38M | 59.89M |
| Operating profit | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M |
| Pretax profit | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M | -73.13M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M | -73.13M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | -1 |
| Diluted EPS | -0.52 | -0.50 | -0.65 | -0.75 | -0.48 | -0.65 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.11M | 3.12M | 42.89M | 56.64M | 22.65M | 144.70M | 221.34M | 660.78M |
| Cash & ST investments | 1.60M | 2.54M | 39.77M | 49.23M | 20.32M | 138.14M | 217.30M | 653.48M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 4.45M | 5.06M | 44.53M | 57.93M | 24.05M | 148.54M | 240.24M | 683.19M |
| Total current liabilities | 1.56M | 1.67M | 3.04M | 9.73M | 7.33M | 21.83M | 54.31M | 44.99M |
| Short-term debt | 612.00K | 451.00K | 479.00K | 317.00K | 229.00K | 310.00K | 63.00K | -- |
| Long-term debt | 325.00K | 113.00K | 134.00K | -- | -- | -- | -- | -- |
| Total liabilities | 29,653,000.00 | 40,690,000.00 | 3,180,000.00 | 9,740,000.00 | 7,393,000.00 | 28,658,000.00 | 59,076,000.00 | 48,845,000.00 |
| Total equity | -25.21M | -35.63M | 41.35M | 48.19M | 16.65M | 119.88M | 181.17M | 634.34M |
| Retained earnings | -26.11M | -36.56M | -54.39M | -79.11M | -116.00M | -222.81M | -515.77M | -728.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 323.13M | 277.43M | 279.92M | 660.78M | 594.31M | 538.45M |
| Cash & ST investments | 317.32M | 268.04M | 272.64M | 653.48M | 582.69M | 520.00M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 342.69M | 296.29M | 299.38M | 683.19M | 619.79M | 565.38M |
| Total current liabilities | 30.80M | 22.88M | 31.45M | 44.99M | 27.41M | 35.71M |
| Short-term debt | -- | -- | -- | -- | -- | 152.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 35,567,000.00 | 27,020,000.00 | 35,458,000.00 | 48,845,000.00 | 31,106,000.00 | 40,301,000.00 |
| Total equity | 307.13M | 269.27M | 263.92M | 634.34M | 588.69M | 525.08M |
| Retained earnings | -557.41M | -600.81M | -658.26M | -728.16M | -782.00M | -855.13M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.41M | -9.60M | -12.13M | -18.23M | -28.69M | -7.57M | -110.79M | -190.92M |
| Depreciation & amortization | 521.00K | 615.00K | 755.00K | 755.00K | 631.00K | 728.00K | 2.10M | 2.96M |
| Free cash flow | -7.63M | -9.83M | -12.72M | -18.31M | -28.94M | -8.40M | -164.30M | -206.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 44.85M | 27.23M | 0 | 125.03M | 250.00M | 678.90M |
| Ending cash balance | 1.70M | 2.64M | 39.87M | 49.33M | 20.42M | 98.78M | 143.45M | 653.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -53.06M | -49.40M | -40.51M | -47.95M | -58.64M | -61.69M |
| Depreciation & amortization | 726.00K | 720.00K | 733.00K | 776.00K | 753.00K | 1.16M |
| Free cash flow | -62.97M | -50.31M | -41.63M | -51.95M | -70.65M | -63.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 172.50M | 0 | 45.90M | 460.50M | 0 | 0 |
| Ending cash balance | 257.71M | 144.09M | 272.85M | 653.69M | 582.90M | 217.92M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -624.22 | -55.20 | -115.73 | -156.45 | -194.63 | -52.09 |
| ROA %i | -176.37 | -219.69 | -71.95 | -48.24 | -91.54 | -123.77 | -150.71 | -46.00 |
| ROIC %i | -- | -- | -516.51 | -55.18 | -114.69 | -156.68 | -198.88 | -54.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -229.25 | -114.82 |
| EBIT margin %i | -- | -- | -- | -- | -- | -781.35 | -3,382.37 | -3,228.83 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.35 | 1.88 | 14.12 | 5.82 | 3.09 | 6.63 | 4.08 | 14.69 |
| Quick ratioi | 1.03 | 1.53 | 13.37 | 5.50 | 2.89 | 6.33 | 4.00 | 14.53 |
| Debt / assetsi | 26.44 | 11.15 | 1.38 | 0.55 | 1.21 | 1.11 | 2.01 | 0.56 |
| LT debt / equityi | -- | -- | 0.32 | -- | 0.37 | 1.12 | 2.63 | 0.61 |
| Interest coveragei | -54.64 | -97.53 | -456.36 | -2,470.10 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -69.21 | -81.20 | -93.04 | -52.09 | -50.14 | -64.03 |
| ROA %i | -61.93 | -71.69 | -80.08 | -46.00 | -46.67 | -59.03 |
| ROIC %i | -72.87 | -84.80 | -96.53 | -54.39 | -52.82 | -67.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,994.30 | -1,784.14 | -2,419.90 | -3,228.83 | -5,947.90 | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.49 | 12.13 | 8.90 | 14.69 | 21.68 | 15.08 |
| Quick ratioi | 10.30 | 11.72 | 8.67 | 14.53 | 21.26 | 14.56 |
| Debt / assetsi | 1.39 | 1.40 | 1.34 | 0.56 | 0.60 | 0.84 |
| LT debt / equityi | 1.55 | 1.54 | 1.52 | 0.61 | 0.63 | 0.87 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development of targeted oncology therapies100.00%
Region
United States100.00%
Quote time 2026-10-08 08:07:56 · For reference only, not investment advice and not tailored to your situation.